Silo Pharma Inc (SILO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Silo Pharma Inc (SILO) has a cash flow conversion efficiency ratio of -0.145x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-822.62K) by net assets ($5.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Silo Pharma Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Silo Pharma Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Silo Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Silo Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Silo Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Silver Elephant Mining Corp
TO:ELEF
|
0.009x |
|
Athena Resources Ltd
AU:AHN
|
-0.044x |
|
Jiankun International Bhd
KLSE:8923
|
-0.018x |
|
Coil S.A./N.V
PA:ALCOI
|
0.006x |
|
International Graphite Ltd
AU:IG6
|
-0.184x |
|
Henderson Smaller Cos Inv Tst
LSE:HSL
|
0.009x |
|
Sego Resources Inc
V:SGZ
|
-0.015x |
|
ARIP Public Company Limited
BK:ARIP
|
0.160x |
Annual Cash Flow Conversion Efficiency for Silo Pharma Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Silo Pharma Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Silo Pharma Inc (SILO) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.31 Million | $-4.66 Million | -0.739x | +2.93% |
| 2024-12-31 | $5.03 Million | $-3.83 Million | -0.762x | -45.89% |
| 2023-12-31 | $6.18 Million | $-3.22 Million | -0.522x | -54.34% |
| 2022-12-31 | $10.34 Million | $-3.50 Million | -0.338x | -34.55% |
| 2021-12-31 | $9.06 Million | $-2.28 Million | -0.251x | +72.18% |
| 2020-12-31 | $1.28 Million | $-1.16 Million | -0.903x | -102.60% |
| 2019-12-31 | $-22.89K | $-794.32K | 34.699x | +5085.55% |
| 2018-12-31 | $407.44K | $272.64K | 0.669x | +382.84% |
| 2017-12-31 | $1.20 Million | $-284.62K | -0.237x | -39.51% |
| 2016-12-31 | $846.51K | $-143.56K | -0.170x | +67.32% |
| 2015-12-31 | $1.96 Million | $-1.02 Million | -0.519x | -15.64% |
| 2014-12-31 | $2.37 Million | $-1.06 Million | -0.449x | -341.92% |
| 2013-12-31 | $1.79 Million | $-181.61K | -0.102x | -119.48% |
| 2012-12-31 | $-41.19K | $-21.47K | 0.521x | -98.03% |
| 2011-12-31 | $-1.75K | $-46.30K | 26.489x | -- |
About Silo Pharma Inc
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's … Read more